<DOC>
	<DOCNO>NCT01843075</DOCNO>
	<brief_summary>This 12-month , multicentre randomise double-blind placebo-controlled Phase IIb study patient mild Alzheimer 's dementia ( AD ) . The investigator aim recruit patient mild Alzheimer 's dementia define National Institute Neurological Communicative Disorders Stroke - Alzheimer 's Disease Related Disorder Association ( NINCDS-ADRDA ) Criteria Probable Alzheimer 's Dementia meeting Dubois criterion early AD , Mini Mental State Evaluation score least 20 maximum 30 CDR Global score 0.5 1 . Patients randomise 1:1 ratio receive liraglutide match placebo .</brief_summary>
	<brief_title>Evaluating Liraglutide Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>1 . Capable give capacity give inform consent 2 . An individual act reliable study partner regular contact ( combination face face visit / telephone contact acceptable ) sufficient subject interaction provide meaningful input rating scale , necessary , supervise perform injection , judge investigator 3 . Diagnosis Probable Alzheimer 's disease accord Dubois criterion ( Dubois , Feldman et al . 2007 ) National Institute Neurological Communicative Disorders StrokeAlzheimer 's Disease Related Disorders Association ( NINCDSADRDA ) criteria 4 . Age 50 year 5 . MiniMental State Examination ( MMSE ) score ≥20 CDRGlobal score 0.5 1 6 . Rosen Modified Hachinski Ischemic score ≤4 7 . On stable medication 2 month screen visit ; cholinesterase inhibitor 8 . Fluency English evidence adequate premorbid intellectual functioning 9 . Likely able participate schedule evaluation complete require test 1 . Patients treatment diabetes mellitus 2 . Any contraindication use liraglutide per Summary Product Characteristics ( hepatic impairment , renal impairment CKD stage 4 ( eGFR &lt; 30 ml/min/1.73m2 ) , inflammatory bowel disease ) . Patients eGFR less 45 ml/min/1.73m2 renal function monitor closely 3 . Significant neurological disease AD may affect cognition 4 . MRI/CT show unambiguous aetiological evidence cerebrovascular disease regard dementia vascular dementia fulfil NINCDSAIREN criterion 5 . Current presence clinically significant major psychiatric disorder ( e.g. , Major Depressive Disorder ) accord criterion Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) 6 . Current clinically significant systemic illness likely result deterioration patient 's condition affect patient 's safety study 7 . History epilepsy , seizure treatment could contribute cognitive impairment 8 . Treatment immunosuppressive medication ( e.g . systemic corticosteroid ) within last 90 day ( topical nasal corticosteroid inhale corticosteroid asthma permit ) chemotherapeutic agent malignancy within last 3 year 9 . Myocardial infarction within last 1 year 10 . History cancer within last 5 year , except localised skin cancer 11 . Other clinically significant abnormality physical , neurological laboratory examination could compromise study detrimental patient 12 . History alcohol drug dependence abuse within last 2 year 13 . Current use anticonvulsant , antiParkinson 's , anticoagulant ( exclude use aspirin 325 mg/day less ) narcotic medication . Subjects anticoagulant allow , arterial line insert 14 . Use experimental medication AD investigational medication device within 60 day . Patients involve monoclonal antibody study exclude unless know receive placebo trial 15 . Women childbearing potential . Women could become pregnant require use adequate contraception throughout trial 16 . Patients personal family history medullary thyroid carcinoma ( MTC ) patient multiple endocrine neoplasia type 2 ( MEN2 ) 17 . Any contraindication MRI scan</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>